From: Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma
Mutational gene | Most frequent subtype | frequency | Frequent mutation in tumour type |
---|---|---|---|
AITL, PTCL-NOS | 42-89%, 28-48, 5% | MPN (~13%), (CMML) (~50%), MDS (25%), AML(~23%) [154] | |
AITL, PTCL-NOS | 25-33%, 27% | AMLs (20–30%), MDS (10–15%) [155] | |
IDH2 | AITL [11] PTCL-NOS | 20-45%, 7.5%156 | AML(8–19%) [157] MDS (~5%) [158] |
KMT2D/MLL2 | All PTCL, AITL, PTCL-NOS | 42%, 25%, 36% | DLBCL (35–85%) [159] FL (89%) [160] |
KMT2C, SETD1B | 8.2%, 5.2% | Breast [161] cancer 8%MLL2+MLL3(16-20%) | |
SETD2 | EATL MEITL | 32%, [83] 21/23 (91%) [84] | Renal cell carcinoma (13-30%) [164] |